

Supplementary Information for
*Nanopanel2 calls phased low-frequency variants
in Nanopore panel sequencing data*

Niko Popitsch^{1,2,*}, Sandra Preuner² & Thomas Lion^{2,3}

¹Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA)
Vienna Biocenter (VBC), Dr. Bohrgasse 3, 1030 Vienna, Austria.

²Children's Cancer Research Institute, Zimmermannplatz 10, 1090 Vienna, Austria.

³Department of Pediatrics, Medical University of Vienna,
Währinger Gürtel 18-20, 1090 Vienna, Austria.

*Corresponding author

Contents

I	Supplementary Text	3
1	Pisces variant calling in short-read WES data	4
2	Long read mapping	4
3	Variant caller comparison	5
3.1	Nanopolish evaluation	5
3.2	Medaka evaluation	5
3.3	Longshot evaluation	6
4	Full virus sequencing evaluation	6
II	Supplementary Tables	7
III	Supplementary Figures	13

Introduction

The following document contains supplementary information and figures for the paper 'Nanopanel2 calls phased low-frequency variants in Nanopore panel sequencing data'. It is split into three parts. Part I contains various text sections providing additional details about the conducted evaluation and nanopanel's algorithms. Parts II + III contain supplementary tables and supplementary figures showing additional data/analyses as referenced throughout the main manuscript.

Part I
Supplementary Text

1 Pisces variant calling in short-read WES data

The following commandline was used to call somatic variants in the oncospan WES dataset with pisces v5.2.9.122

```
pisces -bam bam_file -CallMNVs false -g fasta_file -gVCF false -OutFolder out_dir -RMxNFilter 5,9,0.35  
-MinVF 0.0005 -SSFilter false -MinVQ 0 -MinDepth 5
```

Unfiltered calls were considered as truth set for the oncospan dataset.

2 Long read mapping

Reference genomes

ABL1 data was mapped against *NM_005157.5*, the respective FASTA file can be downloaded from NCBI. The reference sequence for the sequenced Oncospan amplicons was deposited at XXX. The following commandlines were used to map reads using the respective long read mapper:

last v1042

```
last lastal -Q1 last_db fastq_file > tmp_file  
last last-split < tmp_file > maf_file  
last maf-convert SAM maf_file > sam_file
```

We then added missing headers (@HD, @PG, @SQ) to the resulting SAM files, converted them to BAM format and extracted all alignments with maximum alignment score (AS tag) to ensure a single (primary) alignment per read name. Finally, resulting BAM files were sorted and indexed.

ngmlr v0.2.7

```
ngmlr -r fasta_file -q fastq_file -x ont -t threads -o sam_file --no-smallinv --no-lowqualitysplit \  
-k 10 --match 3 --mismatch -3 --bin-size 2 --kmer-skip 1
```

Resulting SAM files were converted to BAM, sorted and indexed.

minimap2 v2.17-r941

```
minimap2 -ax map-ont -t threads fasta_file fastq_file -o sam_file
```

Resulting SAM files were converted to BAM, sorted and indexed.

3 Variant caller comparison

We compared np2 to three state-of-the-art variant callers for Nanopore data (Medaka, Longshot and Nanopolish). This evaluation was restricted to oncospan calls with expected/observed VAF>10% due to technical limitations of the respective callers that were not developed as somatic variant callers (cf. Fig1b in main manuscript). For Nanopolish, for example, we were unable to produce low-VAF calls with Nanopolish because it does not call segments with >200 call candidates (built-in, hard threshold) which we easily exceeded using e.g., a 5% VAF threshold and because Nanopolish does not work with target ploidies>2. All comparisons were conducted on the minimap2 oncospan alignments.

3.1 Nanopolish evaluation

The following commandline was used to create the Nanopolish v0.13.2 call sets:

```
nanopolish variants -o out_file \  
                    -t threads \  
                    -r fastq_file \  
                    -b bam_file \  
                    -g fasta_file \  
                    --min-candidate-frequency 0.1 \  
                    -w roi_interval \  
                    --ploidy 2 \  
                    --calculate-all-support \  
                    --max-haplotypes 1000000 \  
                    -v
```

3.2 Medaka evaluation

Before running Medaka on the minimap2 alignments, we renamed reads with duplicate names using a custom script. The following commandline was used to create the Medaka v1.2.5 call sets:

```
medaka_variant -f fasta_file \  
               -i bam_file \  
               -t threads \  
               -p \  
               -d \  
               -U \  
               -l \  
               -n sample_name \  
               -o sample_name
```

3.3 Longshot evaluation

The following commandline was used to create the Longshot v0.4.3 call sets:

```
longshot --bam bam_file \  
         --ref fasta_file \  
         --out vcf_file \  
         --min_cov 100 \  
         --max_cov 120000 \  
         --force_overwrite \  
         --no_haps \  
         --min_alt_frac 0.01 \  
         --max_snvs 10 \  
         --sample_id sample_name
```

4 Full virus sequencing evaluation

We tested np2's ability to call variants in Nanopore direct RNA sequencing data using the SARS-CoV-2-IVT dataset from [1] (in-vitro transcribed SARS-CoV-2-infected Vero cells). We downloaded raw FAST5 files for the '8F6N9_Korea_IVT.Wuhan_Hu_1' dataset and basecalled them with guppy v4.5.3 (kit: SQK-RNA002, flowcell: FLO-MIN106). We then mapped reads with minimap2 against the NCBI reference sequence NC_045512.2 and annotated the alignments with guppy probabilities. We subsampled this dataset to create 10 alignments with an average read depth of 1500 and called variants with np2 and longshot using default parameters. Np2's SI and SB filters were deactivated for this RNA dataset.

The resulting calls were compared to a reference set of known SARS-CoV-2 variants. This reference set was created by combining (i) all Nextstrain SARS-COV-2 variants with a minimum popAF of 1% that were found in at least two clades with (ii) four expected variants from BetaCoV/Korea/KCDC03/2020 (GISAID; T4402C, G5062T, C8782T, and T28143C). The results of this evaluation are summarized in Sup. Fig. S26.

Part II

Supplementary Tables

List of Tables

S1	Nanopanel2's call quality (Phred score) calculation per variant type in pseudo code.	8
S2	Datasets used in this study	9
S3	Sequenced amplicons	9
S4	Core sequencing statistics per dataset/flowcell	9
S5	Short description of nanopanel2 filters and default thresholds (square brackets). See main manuscript for a more detailed description of AQ1, SB and HP. . . .	10
S6	Description of false negative calls in the oncosopan evaluation datasets. See Sup. Fig. S8 for additional data for these FNs.	10
S7	Compound (A+B) and single (A, B) ABL1 mutations on flowcell 'abl1_min_1'.	11
S8	Compound (A+B) and single (A, B) ABL1 mutations on flowcell 'abl1_min_2'.	11
S9	Clinical sample mutations on flowcell 'abl1_min_3' as validated by Sanger sequencing	12
S10	Clinical sample mutations on flongles 'abl1_flo_1' and 'abl1_flo_2' as validated by Sanger sequencing	12

Variant type	Formula	Rationale
SNV	$quality = \min(100, -\log_{10}(non_alt_prob))$	pileups with high non-alt allele probabilities are unreliable
INS	$data = [1 - \min(hp_len, 5)/5]$ $data+ = [0 \text{ if } seq_eq_ins \text{ else } [1]$ $data+ = [1 - \min(5, abs(aa_skew))/5]$ $data+ = [\min(30, avg_base_qual)/30]$ $quality = \min(100, -10 * \log_{10}(1 - mean(data)))$	long HP => low score ref seq equals inserted bases => low score high aaSkew => low score high avg base quality => high score call quality phred score calculation
DEL	$data = [1 - \min(hp_len, 5)/5]$ $data+ = [1 - \min(5, abs(aa_skew))/5]$ $data+ = [\min(30, avg_base_qual)/30]$ $quality = \min(100, -10 * \log_{10}(1 - mean(data)))$	long HP => low score high aaSkew => low score high avg base quality => high score call quality phred score calculation

Table S1: Nanopanel2's call quality (Phred score) calculation per variant type in pseudo code.

Panel	Dataset	Amplicons	Flowcell	Samples	Multiplexed	Description
ABL1_NM_005157.5	abl1_min_1	1	MinION	12	yes	benchmark variants (single and compound)
ABL1_NM_005157.5	abl1_min_2	1	MinION	12	yes	Dilution series (barcodes 1-6) and ring trial variants (barcodes 7-12)
ABL1_NM_005157.5	abl1_min_3	1	MinION	9	yes	clinical samples (downsampled)
ABL1_NM_005157.5	abl1_flo_1	1	Flongle	1	no	benchmark variants
ABL1_NM_005157.5	abl1_flo_2	1	Flongle	8	yes	clinical samples
Oncospan	onco_20k_1	9	MinION	1	no	benchmark variants
Oncospan	onco_20k_2	9	MinION	1	no	benchmark variants
Oncospan	onco_20k_3	9	MinION	1	no	benchmark variants
Oncospan	onco_20k_4	9	MinION	1	no	benchmark variants
Oncospan	onco_20k_5	9	MinION	1	no	benchmark variants
Oncospan	onco_20k_6	9	MinION	1	no	benchmark variants
Oncospan	onco_100k_1	9	MinION	1	no	benchmark variants

Table S2: Datasets used in this study

Panel	Amplicon	Gene	Length	Mean coverage in 20k oncospan samples
ABL1_NM_005157.5	NM_005157.5	ABL1	5,596	-
Oncospan	ALK	ALK	1,100	20,950
Oncospan	EGFR_1	EGFR	1,010	21,915
Oncospan	EGFR_2	EGFR	990	21,989
Oncospan	EGFR_3	EGFR	1,070	21,311
Oncospan	KIT_1	KIT	1,030	330
Oncospan	KIT_2	KIT	890	22,215
Oncospan	MET_1	MET	990	21,971
Oncospan	MET_2	MET	1,040	21,250
Oncospan	PIK3CA	PIK3CA	1,020	21,143

Table S3: Sequenced amplicons

Dataset	Flowcell	Nanopore Version	Mean read length [bp]	Total Reads	Passed Reads	Failed Reads	Approx Runtime
oncospan	MinION	R9.4.1	1,079	13,572,202	11,691,353	1,880,849	48h
abl1_min_1	MinION	R9.4.1	1,732	887,247	694,525	192,722	24h
abl1_min_2	MinION	R9.4.1	1,606	704,709	535,271	169,438	24h
abl1_min_3	MinION	R9.4.1	1,100	4,702,087	3,688,465	1,013,622	24h
abl1_flo_1	Flongle	R9.4.1	1,540	237,298	144,590	92,708	24h
abl1_flo_2	Flongle	R9.4.1	1,505	375,610	261,154	114,456	24h

Table S4: Core sequencing statistics per dataset/flowcell

ID	Name	Description
AF	Low allele frequency	Raw allele frequency below configured thresholds [SNV: 0.01, DEL: 0.05, INS: 0.03]
DP	Low depth	Raw read depth below configured thresholds [SNV: 10, DEL: 100, INS: 100]
BQ	Low base quality	Mean base quality below configured threshold [12]
SB	Strand bias	Strand bias ($p - value < 0.05$ and $ aa_skew > configured_threshold$) [SNV: 1.0, DEL: 0.2, INS: 0.5]
AQ1	Low allele quality filter1	SNV only: Corrected allele frequency below configured thresholds [0.01] or corrected allele-count below threshold [10]
AQ2	Low allele quality filter2	SNV only: $Corrected_allele_count/raw_allele_count < configured_threshold$ [0.3]
HP	Homopolymer filter	Homopolymer filter, see main manuscript for details
LQ	Low call quality	Call quality below configured threshold [SNV: 10, DEL: 3, INS: 3], see below for details
SI	Strong strand imbalance	Very high/low fraction of plus-strand reads [< 0.2 or > 0.8]

Table S5: Short description of nanopanel2 filters and default thresholds (square brackets). See main manuscript for a more detailed description of AQ1, SB and HP.

Chr	Pos	Ref	Alt	Type	VAF_exp	VAF_obs	Description
PIK3CA	551	G	A	SNV	0.08182	0.008828432	Filtered due to low AF and other filters in 6/7 subsamples; the VAF was approximately 10X underestimated (VAF_obs ~0.9% vs VAF_exp 8%)
MET_2	687	GT	G	DEL	0.05245	0.13694436	Filtered with strand-bias, homopolymer and low call quality filters in all 7 oncospan datasets. The VAF was ~3X overestimated (VAF_obs ~14% vs VAF_exp 5%). An IGV screenshot showing the short-read WES alignment at this position is shown in Sup. Fig S22
KIT_2	501	A	T	SNV	0.07359	NA	Not called in 6/7 subsamples due to too low allele fraction (e.g., in replicate 2: 144/21737 reads)
ALK	135	C	CATTG	INS	0.05469	NA	Not called in 1/7 samples. Instead, a 'C/CGATG' insertion was called in this sample (replicate 2).

Table S6: Description of false negative calls in the oncospan evaluation datasets. See Sup. Fig. S8 for additional data for these FNs.

Sample	Description
S01	E255V 80%, T315I 10%
S02	E255V 70%, E255V+T315I 20%
S03	T315I 80%
S04	T315I 50%
S05	T315I 10%
S06	T315I 3%
S07	T315I 1%
S08	T315I + E255V 80%
S09	T315I + E255V 50%
S10	T315I + E255V 10%
S11	T315I + E255V 3%
S12	T315I + E255V 1%

Table S7: Compound (A+B) and single (A, B) ABL1 mutations on flowcell 'abl1_min_1'.

Sample	Description	Category
S01	T315I+E255V 10%	Dilution series
S02	T315I+E255V 10%	Dilution series
S03	T315I+E255V 3%	Dilution series
S04	T315I+E255V 3%	Dilution series
S05	T315I+E255V 1%	Dilution series
S06	T315I+E255V 1%	Dilution series
S07	M244V 30%, T315I 30%, E282K 20%	Ring trial
S08	M244V 5%, M351T 20%	Ring trial
S09	Y253F 30%	Ring trial
S10	H396P 20%	Ring trial
S11	F311L 5%	Ring trial
S12	L387M 10%	Ring trial

Table S8: Compound (A+B) and single (A, B) ABL1 mutations on flowcell 'abl1_min_2'.

Sample	Description	Patient	Category
S01	N/A	A	minor BCR-ABL
S02	Y253H 83%	A	minor BCR-ABL
S03	Y253H 83%, F317L 7%	A	minor BCR-ABL
S04	T315I 40%, Y253H 82%, F317L 12%	A	minor BCR-ABL
S05	T315I 18%, Y253H 27%, E255V 58%	A	minor BCR-ABL
S06	E255V 100%	A	minor BCR-ABL
S07	T315I 10%	B	major BCR-ABL
S08	N/A	B	major BCR-ABL
S09	T315I 20%, E255K 22%	B	major BCR-ABL

Table S9: Clinical sample mutations on flowcell 'abl1_min_3' as validated by Sanger sequencing

Flongle	Sample	Description
abl1_flo_1	S01	T315I 50%
abl1_flo_2	S01	A269A 100%
abl1_flo_2	S02	M244V 100%
abl1_flo_2	S03	H396R 19%
abl1_flo_2	S04	E255V 100%
abl1_flo_2	S05	T315I 100%
abl1_flo_2	S06	E459K 100%
abl1_flo_2	S07	G250E 51%
abl1_flo_2	S08	E255V 100%, T315I 100%

Table S10: Clinical sample mutations on flongles 'abl1_flo_1' and 'abl1_flo_2' as validated by Sanger sequencing

Part III

Supplementary Figures

List of Figures

S1	Np2 block diagram	15
S2	Probability distributions	16
S3	HP filtered calls	17
S4	Filter distributions	18
S5	Mapping statistics	19
S6	Mapper comparison	20
S7	VAF correlations	21
S8	FN oncospan calls	22
S9	Performance on clinical samples	23
S10	VAF distributions	24
S11	INDEL TPR	25
S12	FP call recurrency	26
S13	False-positive rates	27
S14	Oncospan performance	28
S15	Downsampling recurrency	29
S16	TPR of clinical samples	30
S17	Haplotype map 1	31
S18	Haplotype map 2	32
S19	Haplotype map 3	33
S20	Flongle FP VAF distributions	34
S21	Homopolymer run analysis	35
S22	False negative call example	36
S23	Alignment example	37
S24	Strand imbalance	38
S25	Variant caller comparison example	39
S26	SARS-CoV2 evaluation	40
S27	Haplotype analysis	41




Figure S1: Block diagram showing the core components of Nanopanel2 (np2). Briefly, Nanopore reads are demultiplexed (optional), read bases and guppy basecalling probabilities are aligned to a given amplicon reference sequence and variants and haplotypes are called. See Methods for a detailed description of the individual steps. Np2 is implemented in python3.7 and makes use of external tools as indicated (including samtools and htlib; not shown).




Figure S2: Violin plots showing basecalling probability distributions for reference and alt-allele bases on reads that were called to carry the alt-allele at the respective position by guppy. The plot shows that alt-allele reads at uncalled (TN and FN) positions show elevated ref-allele probabilities indicating that, over all aligned reads, the basecaller was more unsure about calling the alt-allele when compared to the reads at called (TP + FP) positions. This observation forms the basis for our novel allele quality (AQ1) filter that examines the skewness of the allele probability distributions on each individually read in order to decide whether to include or filter it (see main text). Data for this plot were extracted from reads at randomly sampled oncospan 20k calls with a maximum VAF of 10%. Read counts per category are indicated in blue labels.




Figure S3: VAF, hp length and recurrence statistics for all calls from 40 samples that were filtered exclusively by our HP filter. Only 1 of 398 calls (0.25%) was a FN, all other were true negatives. Subfigures a and c show that we found mostly low-frequency calls with a high degree of recurrence (99 distinct calls; one deletion was, e.g., called in 17/40 samples; numbers in square brackets indicate the number of samples a variant was found in) suggesting systematic reasons for such calls that could be exploited for improved filtering. Subfigure b shows a histogram of hp lengths in the context of such calls. For SNVs, the plotted values correspond to the maximum length of an up/downstream hp run). For INDELS, the length is the sum of up- and downstream hp runs of the first base of the respective alt allele (see Methods in main manuscript).




Figure S4: Distribution (UpSet plots, Lex et al., 2014) of filter subsets for TN SNV (a+c) and INDEL (b+d) calls. Filters are described in Table S5. Subplots a and b show the top 25 upsets while subplots c and d show only calls that were filtered by one single filter. The plots reveal that np2's allele quality filter (AQ1) is the single most effective filter for suppressing FP SNV calls followed by strand bias (SB) and homopolymer (HP) filters. INDEL FPs are predominately filtered due to low allele frequency (AF) and also SB and HP filters. Overall, these plots were created from more than 200k individual calls in 40 different samples.




Figure S5: Mapped reads per sample, averaged over all three mappers (mm2, ngm and last) and over all sequenced amplicons.




Figure S6: Subfigures a and b show the numbers of filtered and PASS calls per dataset for oncospan and abl1 data respectively and demonstrate increased numbers of unfiltered (potentially FP) calls resulting from ngm alignments. Subfigure c confirms this finding by showing slightly increased INDEL VAF distributions for ngm vs mm2 alignments. Subfigures d and e show good VAF correlation between ngm and mm2 and lower correlation between mm2 and last.




Figure S7: Correlation between expected (exp) and observed (obs) VAF for different mappers in a dilution series (*abl1_min_2*/dilution; Sup. Table S8) with two replicates and two target variants (E255V + T315I, compound on the same plasmid) with expected 10%, 3% and 1% VAF respectively. Sample S06 (VAF=1%) is missing as none of the respective variants was called by np2. The graph shows the best reproducibility and highest correlation between expected and observed VAF for the minimap2 alignments. It also shows very similar reported VAFs for variants linked on the same plasmid.




Figure S8: FN calls in the oncospan panel (7 replicates). Overall, there were 4 true variants (2 SNVs and 2 INDELS) that were filtered or not called in one or multiple replicates. Subplots a and b show the respective reasons (filters) and the numbers of replicates containing these FNs (number of top of bars). Subplots c and d show observed and expected VAF for these variants. See Sup. Table S6 for a detailed description of these FN calls.






Figure S9: Detailed performance charts showing TP, FP and FN counts for all clinical samples with a known truth set. Subfigure a shows 6 ring trial samples from flowcell `abl1_min_2`. Subfigure b shows 4 clinical samples from flowcell `abl1_min_3` (each sample was downsampled to 25k reads). Subfigure c shows 8 clinical samples from flongle `abl1_flo_2`. Only calls with a VAF > 5% were considered in these plots. Note, that we do not have a complete ground truth for these samples due to limitations of the used validation assays (see main manuscript) which means that some of the called false positives could be true variants. Also, most false-positives have low VAF as demonstrated in Sup. Fig. S10 and Fig. 1d of the main manuscript.

a



b



Filter status



Figure S10: Distribution of observed raw VAF (y-axes; log-transformed) for filtered and unfiltered ('PASS') variants per truth status and variant type for oncospan (a) and *abl1* data (b). Horizontal grey lines show calling thresholds for deletions, insertions and SNVs respectively. The graph demonstrates that np2 produces very few high-frequency FP calls despite the strong overlap of VAF distributions of filtered and unfiltered calls.




Figure S11: True positive rate for three validated INDEL calls over all oncospan replicates.




Figure S12: VAF distributions of putative false-positive calls in the oncospan data (a) and all clinical datasets (b) that are found in more than one sample. The boxplots contain all observed VAFs from all considered datasets and boxes are coloured by variant type. Dotted, dot-dashed and dashed lines indicate the calling thresholds for deletions, insertions and SNVs respectively. Numbers in square brackets indicate the number of datasets a FP was found in (in subfigure c this includes filtered calls). Only one sample per patient was considered for subplots b and c to not artificially inflate the statistics by replicated datasets. Subplot a shows that there are no high-VAF oncospan false positives (max VAF $\sim 8\%$), that most recurrent FP calls are small insertions and that observed allele frequencies are very similar across the 7 replicates (narrow boxes). Subplot b and c confirm that most recurrent FP calls are small, low-frequency INDELS and show one highly recurrent, possibly systematic FP at 1685AG>A which we consider a PCR artefact (called but partially filtered in all 33 considered *abl1* samples). Note that some of the reported FP calls might actually be true but could not be validated due to the detection limits of the used orthogonal technology (e.g., $\sim 20\%$ VAF for Sanger sequencing).




Figure S13: False-positive rates (FPR) per kb per sample for SNVs (a), INDELs (b) as well as overall rates per variant type (c). Note, that for some `abl1_min3` downsamples we observed smaller FPR in samples with lower read counts. Overall, we found median FPR values of 0.95 and 0.7 for SNVs and INDELs respectively for np2's default VAF thresholds. Median FPR was 0 for SNVs and INDELs when applying a VAF threshold of 5%. Subfigure d shows that SNV and INDEL FPR values are weakly correlated.




Figure S14: Number of true positive (TP), true negative (TN) and false negative (FN) variant calls per oncospan dataset, caller and variant type for all calls with an observed or expected (for FN) VAF > 1%. Note that most of the shown FP have low VAF, cf. Fig. 1 in main manuscript.




Figure S15: Variant calls, their VAF and their recurrence across 4 downsamples (1k, 5k, 10k and 25k reads) in four exemplary *abl1* samples from two patients (a+b: patient1, c+d: patient2). Variants are sorted by mean VAF, the number of downsamples a variant was called in is given in square bracket, i.e. a value of 4 corresponds to calls found in all four downsamples. Together, these boxplots show that the estimated variant calls and VAFs are highly reproducible across the downsamples despite the coverage differences and the low coverage of the 1k reads subsample.




Figure S16: True positive rate (TPR) for all downsamples (1k, 5k, 10k and 25k reads) of 4 clinical samples from flowcell `abl1_min_3` with an existing truth set. All but one variant in sample 'abl1_min_3.9' were found in all downsamples. This FN is E255K which is always filtered by our 'HP' filter, see discussion in Methods section of main manuscript.




Figure S17: Haplotype map for samples 1 (a) and 2 (b) of flowcell abl1_min_2. Expected VAF for the compound mutations E255V and T315I was 10% for both samples. Red mutations are false-positives, see caption of main Fig. 2 for a detailed description of our haplotype map format.




Figure S18: Haplotype map for samples 3 (a) and 4 (b) of flowcell `abl1_min_2`. Expected VAF for the compound mutations E255V and T315I was 3% for both samples. Red mutations are false-positives, see caption of main Fig. 2 for a detailed description of our haplotype map format.

a




Figure S19: Haplotype map for sample 5 of flowcell abl1_min_2. Expected VAF for the compound mutations E255V and T315I was 1%. Sample 6 (a replicate of sample 5) is not shown as np2 called none of the two TP mutations in this replicate. Red mutations are false-positives, see caption of main Fig. 2 for a detailed description of our haplotype map format.




Figure S20: Subfigure a plots VAF of TP and potential FP calls in the flongle datasets (abl1_flo_1: 1 benchmark sample, abl1_flo_2: 8 clinical samples from 8 different patients). Subfigure b plots recurrence of FP calls (number of samples containing a variant given in square brackets; cf. Sup. Fig S12 for a detailed explanation of these plots) and shows the same deletion at 1685AG>A as found in all other abl1 samples which we consider a PCR artefact (cf. Sup. Fig S12 b + c). All other recurrent FPs are low VAF insertions and SNVs. Note that we don't know whether all low-frequency FP variants are actually false-positives due to the detection limits of the used validation methods.




Figure S21: Subfigures a and b show median raw and corrected VAF (red line) around homopolymer runs with a minimum length of 3. The X-axis shows genomic positions relative to start/end of hp runs where -1/+1 refer to the first/last base of the hp run respectively (dashed black lines) and all bases in the "body" of the hp run are averaged and summarised at position zero. The figure shows that our correction algorithm filters around two-thirds of base calls and overall results in relatively increased VAF around hp run borders. Note that these positions also show increased average base qualities (c). Subfigure d shows a histogram of all hp runs per amplicon. Labels in the plots show the fraction of amplicon bases in the respective hp runs. Subfigures a-c were calculated from 40 samples containing data of over 5500 hp runs.




Figure S22: IGV screenshot of the oncospan WES data showing a 1bp deletion at MET_2:687GT>G. The deletion is clearly visible and was called by pisces in the deep short read alignment (read depth: 572, VAF=0.05245) but filtered by np2 resulting in a FN call, cf. Sup. Table S6.




Figure S23: IGV screenshot demonstrating local differences in read alignment that result in differing overall performance of the respective mappers. Shown tracks (from top) are: (i) pisces calls from the WES data (truthset) in the ALK amplicon of an oncospan 20k replicate, (ii) sufficiently covered regions in WES data, (iii) np2 calls resulting from mm2 (top) and ngm (bottom) alignments. Filtered and unfiltered calls are shown as light-blue and dark-blue rectangles respectively. The screenshot shows a single true-positive INDEL call in the mm2 alignment (green arrow) while the same INDEL is shifted to the right in ngm due to its different alignment algorithm and filtered by np2 (red arrow).




Figure S24: Imbalance of read counts per strand for all datasets/samples: $\log_2(\text{\#plus_strand_reads} / \text{\#minus_strand_reads})$. Please note that nanopanel2 corrects for this sample-wide imbalance to avoid over-filtering due to strand bias (see Methods in main manuscript).




Figure S25: IGV screenshot showing variant calls from np2, Medaka, Longshot and Nanopolish on the ALK amplicon. Reference pisces calls from deep WES Illumina data are shown in the top panel. For the performance evaluation in Fig1b of the main manuscript, only reference calls with an expected VAF $\geq 10\%$ were considered.




Figure S26: Nanopanel2 and longshot evaluation on full virus sequencing data. We tested np2’s ability to call variants in Nanopore direct RNA sequencing data using subsamples of the SARS-CoV-2-IVT dataset from [1] (in-vitro transcribed SARS-CoV-2-infected Vero cells), see Section 4 for a description of how these data were prepared. Np2 and longshot variant calls were compared to a reference set that was created by combining (i) all Nextstrain SARS-CoV-2 variants with a minimum popAF of 1% that were found in at least two clades with (ii) four expected variants from BetaCoV/Korea/KCDC03/2020 (GISAID; T4402C, G5062T, C8782T, and T28143C). Subfigure a shows that np2 called about a third (~49) of all reference variants (ALL) across the 10 subsamples although several were filtered while longshot recovered only about 4% (~6) of all reference variants of which some were filtered by the ‘dn’ (‘dense cluster of variants’) filter. When considering only PASS calls above a 10% VAF threshold (ALL_PASS_VAF10), np2 and longshot detect a mean of 8.9 and 2.8 reference variants respectively. Both algorithms called all 4 expected variants (EXP), however 1 was filtered by np2’s HP filter and 2-3 by longshot’s ‘dn’ filter. Subfigure b shows good correlation between the called PASS variants shared by both callers. Subfigure c shows the positions of all reference variants (grey dots) and the four expected variants (black dots) on the x-axis and the VAFs of np2 (blue dots/triangles) and longshot (red dots/triangles) calls for 1 downsampled replicate on the y-axis. The grey dashed line depicts a 10% VAF threshold.




Figure S27: Observed vs expected haplotype fractions for compound and single mutation ABL1 samples in flowcells `abl1_min_1` and `abl1_min_2`. Observed haplotype fractions are slightly underestimating expected fractions in most cases as partial haplotypes (e.g., reads that don't span both mutations or reads with deletions at variant positions) are not considered in this analysis.

Bibliography

- [1] Kim, D. *et al.* The architecture of SARS-CoV-2 transcriptome. *Cell* **181**, 914–921.e10 (2020).